Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Adc Therapeutics Sa (NY: ADCT ) 3.070 +0.250 (+8.87%) Official Closing Price Updated: 7:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Adc Therapeutics Sa < Previous 1 2 3 4 5 6 7 8 Next > ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting March 05, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference February 27, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics - Time For A Turn-Around? February 27, 2024 ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. Via Talk Markets Alaska Air To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday February 20, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Analyst Expectations for ADC Therapeutics's Future November 20, 2023 Via Benzinga The Latest Analyst Ratings for ADC Therapeutics September 12, 2023 Via Benzinga A Preview Of ADC Therapeutics's Earnings August 07, 2023 Via Benzinga 4 Analysts Have This to Say About ADC Therapeutics July 25, 2023 Via Benzinga The 3 Biotech Stocks That Could Make Your February Unforgettable February 15, 2024 After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. Via InvestorPlace The 3 Most Undervalued Biotech Stocks to Buy in February 2024 February 08, 2024 With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider. Via InvestorPlace ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards January 04, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Provides Business Updates January 04, 2024 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL) December 12, 2023 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards November 07, 2023 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates November 07, 2023 From ADC Therapeutics SA Via GlobeNewswire Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket November 06, 2023 Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger... Via Benzinga ADC Therapeutics to Participate in the Jefferies London Healthcare Conference November 06, 2023 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting November 02, 2023 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023 October 24, 2023 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Participate in September Investor Conferences September 05, 2023 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) August 30, 2023 From ADC Therapeutics SA Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023 August 10, 2023 Via Benzinga ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates August 08, 2023 From ADC Therapeutics SA Via GlobeNewswire ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023 August 01, 2023 From ADC Therapeutics SA Via GlobeNewswire Stocks That Hit 52-Week Lows On Tuesday July 25, 2023 On Tuesday, 56 companies set new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Monday July 24, 2023 On Monday morning, 70 companies achieved new lows for the year. Via Benzinga Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma July 24, 2023 From ADC Therapeutics SA Via GlobeNewswire Stocks That Hit 52-Week Lows On Friday July 21, 2023 On Friday, 54 companies hit new 52-week lows. Via Benzinga ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths July 21, 2023 ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with... Via Benzinga ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients July 20, 2023 From ADC Therapeutics SA Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.